Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas

Central Nervous System Tumors

TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data

Crit Rev Oncol Hematol.

Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Chan AKY, Park CK, Fung KM, Hassell L

doi: 10.1016/

Central Nervous System Tumors

Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics

J Neurooncol.

Bahrami N, Hartman SJ, Chang YH, Delfanti R, White NS, Karunamuni R, Seibert TM, Dale AM, Hattangadi-Gluth JA, Piccioni D, Farid N, McDonald CR

doi: 10.1007/s11060-018-2908-3.

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Central Nervous System Tumors

Correlation of immune phenotype with IDH mutation in diffuse glioma

Neuro Oncol.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M

doi: 10.1093/neuonc/nox054.

Central Nervous System Tumors

Prognostic impact of distinct genetic entities in pediatric diffuse glioma WHO-grade II - report from the German/Swiss SIOP-LGG 2004 cohort

Int J Cancer.

Falkenstein F, Gessi M, Kandels D, Ng HK, Schmidt R, Warmuth-Metz M, Bison B, Krauss J, Kortmann RD, Timmermann B, Thomale UW, Albert MH, Pekrun A, Maaß E, Gnekow AK, Pietsch T

doi: 10.1002/ijc.32995.

Skin Cancer

Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma

Ann Oncol.

Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn J, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R

doi: 10.1093/annonc/mdx717.

SPECIAL REPORT

Multiple Myeloma (MM)

Traitement du myélome multiple récidivant/réfractaire

Central Nervous System Tumors

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial

JAMA Oncol.

Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao A, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA

doi: 10.1001/jamaoncol.2020.3161.

Central Nervous System Tumors

The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study

Neuro Oncol

Ius T, Ng S, Young JS, Tomasino B, Polano M, Ben-Israel D, Kelly JJP, Skrap M, Duffau H, Berger MS

doi: 10.1093/neuonc/noab210

Related content

TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data

Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics

Recent Developments in Metastatic Breast Cancer

Correlation of immune phenotype with IDH mutation in diffuse glioma

Prognostic impact of distinct genetic entities in pediatric diffuse glioma WHO-grade II - report from the German/Swiss SIOP-LGG 2004 cohort

Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma

Traitement du myélome multiple récidivant/réfractaire

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial

The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study